TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03430232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level 1
Description: Short infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level 2
Description: Short infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level 3
Description: Short infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level 4
Description: Short infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level 5
Description: Short infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level 6
Description: Short infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level 7
Description: Short infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level 8
Description: Short infusion of a solution for intravenous administration
Study: NCT01321866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty
Description: Angioplasty of fistula stenosis using a cutting balloon
Study: NCT02810925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypocaloric 1200 Kcal/day diet
Description: Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hypocaloric 1200 Kcal/day diet
Description: Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normocaloric 2000 Kcal/day diet
Description: Patients follow a Normocaloric 2000 Kcal/day diet during 12 weeks.
Study: NCT03430232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level A
Description: Long infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level B
Description: Long infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level C
Description: Long infusion of a solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
Study: NCT02239952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg once daily, oral use for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: 300 mg, once daily, oral use for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg, once daily, oral use for 14 days
Study: NCT00004050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leuvectin
Description: Leuvectin injected intratumorally followed by prostatectomy
Study: NCT00379912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (Monotherapy)
Description: Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
Study: NCT00206440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: nexium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
Study: NCT00942825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP501 + Cisplatin + Pemetrexed
Description: CBP501, pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. CBP501 25 mg/m² will be administered as an i.v. infusion of 1 hour.~2. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes, immediately after the CBP501 infusion.~3. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin + Pemetrexed
Description: Pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes.~2. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion.
Study: NCT03577678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to fix lateral half prosthesis for clavicle
Description: Surgery to fix lateral half prosthesis for clavicle
Study: NCT04332328

Intervention type: DIETARY_SUPPLEMENT
Intervention: Diet
Description: Group of diet types

Intervention type: DIETARY_SUPPLEMENT
Intervention: Diet
Description: Group of diet types
Study: NCT03666169

Intervention type: OTHER
Intervention: Survey
Description: Survey
Study: NCT01321866

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty
Description: Angioplasty of fistula stenosis using a non-cutting balloon
Study: NCT01023165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Humulin, Humalog, Novolog
Description: Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
Study: NCT02752191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferumoxytol
Description: ferumoxytol as an MRI contrast agent infused over several minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadofosveset
Description: gadofosveset as an MRI contrast agent injected over several seconds
Study: NCT02965443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 mg + Saxagliptin 5 mg
Description: 24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 10 mg + Placebo 2 5 mg
Description: 24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
Study: NCT04765358

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Clinic
Description: CGM, Clinical Care Support and Behavioral Health Support
Study: NCT02731729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Study: NCT01724723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir (BARACLUDE®)
Description: entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
Study: NCT00561041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief phone aftercare intervention
Description: Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual aftercare therapy
Description: composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
Study: NCT01545401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMPOWER-PAR Intervention
Description: Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~* Global CV Risks Self-Management Booklets~* CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention
Study: NCT01752244

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: Alfacalcidol
Study: NCT03311295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTO System
Description: The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
Study: NCT02159872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
Study: NCT00579514

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: PCR/PCR/LDR Strategy
Description: Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: PCR/PCR/LDR Strategy
Description: Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
Study: NCT02425670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMSCs
Description: 30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
Study: NCT03854669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pain reporting accuracy
Description: pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
Study: NCT00684658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeenCope
Description: Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Managing Diabetes
Description: Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
Study: NCT00941083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (Use RAL as a simplification strategy)
Description: RAL QD: RAL 800 mg/24 hs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir (Use RAL as a simplification strategy)
Description: RAL BID 400 mg/12 hs
Study: NCT00917943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Counseling Intervention Arm
Description: Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
Study: NCT01047254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elontril
Description: flexible dose of Bupropion 150-300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02852239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: Single dose dabrafenib 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: Single dose dabrafenib 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: Single dose dabrafenib 100 mg
Study: NCT02960191

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Study: NCT03242291

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional resin-based flowable composite
Description: assessment of marginal integrity of Conventional resin-based flowable composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resin-based flowable composite
Description: assessment of marginal integrity of Conventional resin-based flowable composite

Intervention type: OTHER
Group type: OTHER
Intervention: Hydroxyapatite Nanofiber reinforced flowable composite
Description: assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyapatite Nanofiber reinforced flowable composite
Description: assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
Study: NCT03163823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proloquo2Go
Description: Use of communication application Proloquo2Go modified for the ICU setting on an iPad device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care communication methods
Study: NCT03857126

Intervention type: OTHER
Intervention: Signal acquisition
Description: ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).
Study: NCT01156129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stool softener
Description: ducosate sodium, Milk of Magnesia, dulcolax

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm B: Acupressure bracelet
Description: Bioband

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sugar free gum
Description: Orbit
Study: NCT00245492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy
Description: Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
Study: NCT04468139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Dietary Supplement: Quercetin Treatment a daily dose of quercetin (500 mg) will be taken orally by proven COVID-19 cases intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bromelain
Description: Dietary Supplement:Bromealin Treatment a daily dose of bromelain(500 mg) will be taken orally by proven COVID-19 cases intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: vitamin c 1000 mg orally daily by proven COVID-19 cases intervention
Study: NCT00941083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (Use RAL as a simplification strategy)
Description: RAL BID to QD
Study: NCT04552938

Intervention type: OTHER
Intervention: pre-LVA
Description: Venous serum samples were collected from patients before LVA.

Intervention type: OTHER
Intervention: post-LVA
Description: Venous serum samples were collected from patients one-month after LVA.
Study: NCT05658744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video group
Description: Insulin administration video was sent to the mobile phones of the patients assigned to the video group
Study: NCT01366118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic target tailored chemotherapy
Description: All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.~Ch combination schema was customized based on:~Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.~When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen
Study: NCT01751256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration
Description: Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
Study: NCT04625608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Standard care of 3 ml/kg water, plus 15 mg/kg oral paracetamol suspension, a minimum of 1 hour prior to the induction of general anaesthesia.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care of 3.6 ml/kg water, a minimum of 1 hour prior to the induction of general anaesthesia.
Study: NCT02147574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-peristaltic ileosigmoid anastomosis
Description: 1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
Study: NCT05674682

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HIV testing
Description: venipuncture or digital puncture for HIV testing
Study: NCT02748746

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio Impedance Analysis Measurement
Description: Self-adhesive electrodes will be placed to related side's hand dorsum and foot dorsum regarding to calculate for left or right upper extremity's impedance. After completing the measurements for each side, results will be saved by device and documented on paper. A patient total measurement time lasts approximately 3 minutes.